CCO_M_Bone_Health_Lung_Slides.ppt

* * BL, baseline; CI, confidence interval; Cr, creatinine; NSCLC, non-small-cell lung cancer; NTx, N-telopeptide; RR, relative risk; ZOL, zoledronic acid. * ECOG PS, Eastern Cooperative Oncology Group performance score; NSCLC, non-small-cell lung cancer; NTx, N-telopeptide; ZOL, zoledronic acid. NSCLC, non-small-cell lung cancer; NTx, N-telopeptide; SRE, skeletal-related event; ZOL, zoledronic acid. * NSCLC, non-small-cell lung cancer. * * NSCLC, non-small-cell lung cancer; ZOL, zoledronic acid. * * * ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small-cell lung cancer; NTx, N-telopeptide; ONJ, osteonecrosis of the jaw; PD, progressive disease; PS, performance status; SRE, skeletal-related event. * TTP, time to progression. * Mets, metastases; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; q3-4w, every 3-4 weeks; SRE, skeletal-related event; TTP, time to progression. * CI, confidence interval; NR, not reached; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival. * Mets, metastases; NSCLC, non-small-cell lung cancer; NTx, N-telopeptide; OS, overall survival; q3mos, every 3 months; SRE, skeletal-related event. * SRE, skeletal-related event. * * SRE, skeletal-related event. RANK, receptor activator of nuclear factor kappa-B. * RANK, receptor activator of nuclear factor kappa-B; TNF, tumor necrosis factor. * * * IV, intravenous; q4w, every 4 weeks; SC, subcutaneous; SRE, skeletal-related event. ECOG, Eastern Cooperative Oncology Group; SRE, skeletal-related event. * CI, confidence interval; HR, hazard ratio; NS, not significant; SRE, skeletal-related event. * CI, confidence interval; SRE, skeletal-related event. * CI, confidence interval; HR, hazard ratio. * CI, confidence interval; HR, hazard ratio; OS, overall survival. * * CI, confidence interval; HR, hazard ratio; SRE, skeletal-related event. * Denosumab vs Zoledronic Acid: OS in Lung Cancer Scagliotti G, et al. 2011 World Congres